Oumaima Laghzali

Mrs. Oumaima Laghzali


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SLSiqin Liu
Siqin Liu
OLOumaima Laghzali
Oumaima Laghzali
SSShahriar Shalikar
Shahriar Shalikar
MRMara-Camelia Rusu
Mara-Camelia Rusu
LCLucie Carrier
Lucie Carrier
MKMin-Chi Ku
Min-Chi Ku
Hypertrophic cardiomyopathy (HCM) is often characterized by augmented cardiac contractility, which frequently remains undetectable in its early stages. Emerging evidence suggests that hypercontractility is linked to mitochondrial defects that develop early in HCM progression. However, imaging markers for identifying these early alterations in myocardial function are lacking. We used cardiac magnetic resonance feature tracking (CMR-FT) to assess myocardial strain in a Mybpc3-knockin (KI) mouse model that mimicked human HCM. While homozygous (HOM) mice exhibited cardiac hypertrophy, heterozygous (HET) mice represented an early, asymptomatic stage of HCM. To explore mitochondrial contributions to hypercontractility, we evaluated mitochondrial integrity via scanning electron microscopy (SEM) and correlated these findings with strain abnormalities. Young HET female, but not male mice exhibited significant torsion abnormalities (p = 0.02), reduced left ventricular global longitudinal strain (LVGLS, p = 0.009), and impaired right ventricular global longitudinal strain (RVGLS, p = 0.035) compared to the controls. Strain abnormalities correlated strongly with mitochondrial morphological alterations, including changes in volume and area distribution (R > 0.7). Abnormal myocardial strain patterns, including torsion and GLS, serve as early markers of HCM and are closely associated with underlying mitochondrial dysfunction. The HET Mybpc3-KI HCM model provides important insights into the initial stages of HCM progression, highlighting strain abnormalities and sex-specific differences to enhance early diagnosis and therapeutic strategies.

19 November 2025 in JACC: Advances
Verified
Journal Article
Open access
OLOumaima Laghzali
Oumaima Laghzali
DKDanielle Kara
Danielle Kara
SCShi Chen
Shi Chen
SLSiqin Liu
Siqin Liu
SSShahriar Shalikar
Shahriar Shalikar
CNChristopher Nguyen
Christopher Nguyen
Hypertrophic cardiomyopathy (HCM) diagnosis often occurs after myocardium thickening develops, delaying intervention. Cardiac diffusion tensor imaging (cDTI) detects microstructural myocardial remodeling, offering potential for improved risk stratification, especially in patients with preserved ejection fraction. The objective of the study was to determine whether cDTI-derived fractional anisotropy (FA), mean diffusivity, and helix angle (HA) identify myocardial disarray and structural remodeling in HCM in patients and in mouse models. Cardiovascular magnetic resonance imaging at 3T with cDTI (FA, mean diffusivity, and HA) and cine imaging was performed in 10 HCM patients with prior late gadolinium enhanced imaging and 10 healthy volunteers. In parallel, 6 myosin binding protein C3-knock-in and 6 wild-type mice (7-8 weeks) underwent cine-cardiovascular magnetic resonance imaging (9.4 T), ex vivo cDTI, scanning electron microscopy, and histology for microstructural, collagen area fraction and fibrosis analysis. HCM patients exhibited reduced FA vs controls (0.29 ± 0.03 vs 0.34 ± 0.02; P = 0.002), correlating with strain impairment (R2 = 0.67; P = 0.003) and reaching the lowest value in patients with late gadolinium enhancement (P = 0.02). In knock-in mice, the reduction in FA mirrored the human findings. However, additional alterations were observed, including elevated HA transmurality, significant systolic dysfunction, and a strong correlation between FA and interstitial fibrosis. FA may reflect critical aspects of myocardial remodeling in HCM, including fibrosis, and mechanical dysfunction, as demonstrated in both preclinical and clinical settings. Its ability to detect abnormalities even in patients with preserved ejection fraction supports its potential as a translational marker for risk stratification and guiding therapeutic intervention.

14 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
OLOumaima Laghzali
Oumaima Laghzali
SSShahriar Shalikar
Shahriar Shalikar
SLSiqin Liu
Siqin Liu
SLSandra Lehmann
Sandra Lehmann
JPJoao dos Santos Periquito
Joao dos Santos Periquito
MKMin-Chi Ku
Min-Chi Ku
Background/Objectives: While T2* mapping effectively assesses cerebral blood oxygenation, its utility for capturing cardiac phase-dependent myocardial changes in hypertrophic cardiomyopathy (HCM) is underexplored. This study investigates T2* dynamics in an HCM mouse model, to validate T2* as a clinically relevant biomarker for improved HCM diagnosis and treatment monitoring. Methods: A cardiac-specific Mybpc3 genetic mouse model, closely mirroring human HCM, was used with 12 young mice (6–11 weeks old), including both male and female wild-type (WT) and Mybpc3-KI (HCM) groups. The cardiac function was assessed using self-gated multi-slice 2D CINE imaging. To investigate myocardial T2* variations across the cardiac cycle, multi-gradient echo (MGE) imaging was employed. This approach used retrospective gating and continuous acquisition synchronization with pulse oximetry at 9.4 T small animal MRI. Results: Mybpc3-KI mice demonstrated left-ventricular (LV) hypertrophy compared to WT (HCM = 50.08 ± 4.68 µm/g vs. WT = 45.80 ± 20.07 µm/g, p < 0.01) and reduced ejection fraction (HCM = 38.55 ± 5.39% vs. WT= 72.53 ± 3.95%, p < 0.01). Myocardial T2* was significantly elevated in HCM across all cardiac phases (HCM = 12.14 ± 1.54 ms vs. WT = 7.93 ± 1.57 ms, p = 0.002). Strong correlations were observed between myocardial T2* and LV mass (rho = 0.88, p = 0.03). Conclusions: T2* was elevated in HCM with increased LV mass, highlighting the potential of T2* MRI as a sensitive biomarker for distinguishing healthy mice from those with HCM and revealing possible myocardial abnormalities.